Renesis 100 mg (Tablet)
Unit Price: ৳ 600.00 (2 x 3: ৳ 3,600.00)
Strip Price: ৳ 1,800.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Roxadustat |
| Company | Beacon pharmaceuticals plc |
| Also available as |
Indications
- Treatment of adult patients with symptomatic anemia associated with chronic kidney disease (CKD)
Description
- First-in-class orally administered HIF-PH inhibitor
- Promotes erythropoiesis through increasing endogenous production of erythropoietin
- Improves iron regulation
- Overcomes EPO-suppressive effects of inflammation on hemoglobin synthesis and red blood cell production
Pharmacology
- Orally bioavailable
- Hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI)
- Increases endogenous erythropoietin production
- Reduces expression of the peptide hormone hepcidin
- Improves iron availability and boosts hemoglobin levels
- Induces coordinated erythropoiesis
- Increases red blood cell count
- Maintains plasma erythropoietin levels within or near normal physiologic range
- Reduces dysregulation of iron metabolism associated with CKD
- Reduces cholesterol levels
Dosage & Administration
- Orally taken three times per week and not on consecutive days
- Individualized to achieve and maintain target Hb levels of 10 to 12 g/dL
- Usual starting dose is 50 mg three times weekly for patients not on erythropoiesis-stimulating agent treatment
- Usual starting dose is 70 or 100mg three times weekly for patients switching from erythropoiesis-stimulating agents
- Dose adjustment based on Hb monitoring
- Tablet to be taken orally with or without food
Interaction
- May have drug-drug interaction with various medications
- Requires adjusting the dose based on specific drug interactions
Side Effects
- Hypertension
- Vascular access thrombosis
- Diarrhoea
- Peripheral oedema
- Hyperkalaemia
- Nausea
Pregnancy & Lactation
- Contraindicated during pregnancy and breast-feeding
Precautions & Warnings
- May initiate thrombotic vascular events (TVEs), especially in patients with pre-existing risk factors for TVE
- Use caution in patients with a history of seizures
- Not to be administered in case of serious signs and symptoms of infection or liver disorder
- Not to be initiated in pregnant women
Use in Special Populations
- Not indicated in children
- Not recommended for use in patients with severe hepatic impairment
Overdose Effects
- Increased heart rate
- Likely increase in hemoglobin concentration
- Treatment involves appropriate measures of dose reduction or interruption
Therapeutic Class
- Drugs for Haemolytic Hypoplastic & Renal Anemia
Storage Conditions
- Store in a cool (below 30°C), dry place, away from light and moisture
- Keep out of the reach of children